The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...

Allogeneic stem cell therapy allows "off the shelf" cells ... In the likely event of an EU licence for the therapy, Takeda will pay a 15 million euro fee to Tigenix. Apart from affecting the ...

Before Plump joined Takeda, the company was a small-molecule ... microbiome-based medicines, multiple cell therapy platforms, plasma-derived therapies and vaccines. Now, they are back down to ...

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased ...

The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia ...

BBM will work together with Takeda China to accelerate the rapid implementation of this innovative therapy. In the future ...

(Image Credits: Pixabay) The global cell and gene therapy (CGT) market is poised ... This approval was followed by Takeda Pharmaceuticals’ Alofisel (darvadstrocel), which received approval ...

BBM will work together with Takeda China to accelerate the rapid implementation of this innovative therapy ... human coagulation FIX gene into liver cells of patients. Then, coagulation FIX ...